Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Acimtamig by Affimed for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
Acimtamig by Affimed for Cutaneous T-Cell Lymphoma: Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase...
Acimtamig by Affimed for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to...
Acimtamig by Affimed for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Acimtamig by Affimed for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to...
Acimtamig by Affimed for Transformed Mycosis Fungoides: Likelihood of Approval
Acimtamig is under clinical development by Affimed and currently in Phase II for Transformed Mycosis Fungoides. According to GlobalData, Phase...